| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO | Corp VP, CMO
2 companies
Raymond W. Urbanski last filed a Form 4 in August 2024, as CEO at GTBP. The filings on record cover 2 companies. Raymond W. Urbanski's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,351,918 shares of GTBP. The GTBP filings lean toward selling, a net 176,980 shares.
Raymond W. Urbanski has 4 Form 4 filings on record from February 2016 to August 2024, across 3 companies: Chief Development Officer at Soleno Therapeutics (SLNO), 2024; CEO at GT Biopharma (GTBP), 2019; Corp VP, CMO at Mannkind (MNKD), 2016–2017.
The 4 reported transactions were 2 option or other derivative awards and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $517.
The largest open-market sale was 296 shares of MNKD at an average $1.15 on August 10, 2017, about $340.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.